


PLATELET ADDITIVE SOLUTION



WORLDWIDE PRESENCE

Since 2002, more than 7 million units of Macopharma Platelet Additive Solution have been distributed in more than 40 countries.



SSP+ is a CE marked medical device.
It is not available for sale in the United States.
Please refer to the Instructions for Use

MACO PHARMA
Rue Lorthiois
F-59420 Mouvaux (France)
www.macopharma.com



X13AA01D 06/2017 - RCS : 391 600 905 Lille Métropole



SSP+ ADDITIVE SOLUTION

LEAD THE WAY IN BLOOD SAFETY



PRINCIPLE OF ACTION

Platelet Concentrates and Platelet Additive Solution: What are they for?

Platelet concentrates (PC) are notably used for the prevention and treatment of bleeding complications in thrombocytopenic patients. Therefore platelet quality, function, storage stability, morphology and cell integrity needs to be well maintained during processing and storage. Platelet Additive Solution SSP+ (PAS III-M/PAS E* generation) was developed to improve storage stability of buffy-coat and aphaeresis PCs for up to seven days after collection. With SSP+, platelets quality is maintained even under stressful conditions like interruption of agitation or pathogen inactivation^{1,2}. The possible ratio is up to 80% SSP+ / 20% plasma.

SSP+ Formulation

Concentration of electrolytes (mmol/L)



SODIUM CHLORIDE	69.3
CITRATE	10.8
ACETATE	32.5
PHOSPHATE	28.2
POTASSIUM	5.0
MAGNESIUM	1.5

Effects on Platelet metabolism³ and on Platelet membrane function⁴⁻⁷

Phosphate: stimulates glycolysis to produce more lactic acid, acts as a buffer to prevent fall in pH, and is of importance in maintaining good *in vitro* characteristics during interruption of agitation.

Acetate: is used as a substrate for platelet metabolism; it reduces production of lactate by platelets and by formation of bicarbonate, and it maintains stable pH levels during storage of platelet concentrates.

Citrate: prevention of coagulation.

Magnesium: prevents aggregates, reduces platelet-derived cytokines, and reduces activation of platelets.

Potassium: prevents aggregates, reduces activation of platelets, reduces glycolysis (reduced glucose consumption & lactate production), better maintenance of pH levels.
The combined action of potassium and magnesium maintains viability of platelets and limits their activation.

Efficient replacement of up to 80% of plasma in platelet concentrates

Patient safety is our priority

Platelet quality and recovery in SSP+ is equivalent to platelets stored in 100% plasma

Benefits

Patient safety:

Reduced plasma volume to decrease adverse events⁸⁻¹¹ (TRALI, ABO mismatch):** To reduce transfusion risks, the New Zealand Blood Service took the decision to progressively move to provision of platelets suspended in additive solutions, and chose SSP+ for 100% of their needs. From the beginning of the use of SSP+, there was no reporting on transfusion reactions related to the platelet solution¹².

Improved bacterial detection performance^{13,14}: Due to the presence of proteins, nutrients (including glucose) in plasma, the contaminating bacteria form a biofilm which attaches on the surface of the bag container evading detection by sampling. PAS reduces biofilm-formation in platelet concentrates (PCs) while improving bacteria distribution in contaminated PCs. This might be associated with increased availability of bacteria for detection.

Equivalent platelet recovery and CCI (Corrected Count Increment)¹⁵: There is no statistically significant difference of recovery and CCI between PCs stored in SSP+ and PCs stored in plasma.

Blood bank efficiency:

Compatible with all technologies for preparation of platelet products¹⁶⁻¹⁹ (e.g. automated devices for whole blood and aphaeresis derived platelets).

Compatible with Pathogen Inactivation Treatment²⁰⁻²⁴
SSP+ has been validated with all pathogen inactivation technologies (Mirasol, Intercept, THERAFLEX UV-Platelets).

Streamlined blood bank organisation


Having a large volume of available plasma as a blood product for transfusion or for fractionation²⁵⁻²⁶.

Platelet quality is maintained even under stressful conditions: PCs in SSP+ can sustain at least 4 days without agitation during a 7-day storage period¹.

Reduction of discard-rate due to expiry: compatibility with extended platelet shelf life up to 7 days²⁷.

Platelet Quality with SSP+

SSP+ is recognized as the most suitable additive solution on the market that helps standardise platelet concentrates and improves storage conditions. *In vitro* quality^{2,27,28,29,30} and post-transfusion recovery¹⁵ of SSP+ platelets is well maintained. Both, Buffy-Coat and Aphaeresis derived platelets perform at least as well as platelets stored in 100% plasma³¹.



In vitro quality of buffy-coat derived platelets
(data provided by Red Cross Blood Services NSTOB, Springe, Germany)

Specifications

- Class III Medical Device.
- 2 year shelf-life => Available volumes: 250, 280, 300, 500 mL.
- 1 year shelf-life => Available volumes: 200, 220 mL.
- 16 product codes.
- Polyolefin container (Non-PVC).
- Barcode ISBT 128.
- Full connectivity: tubing for sterile connection, luer-lock for easy connection to aphaeresis kits.
- Steam sterilised.

BIBLIOGRAPHY

1. Van der Meer PF, Gulliksson H, AuBuchon JP, Prowse C, Richter E, de Wildt-Eggen J, for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. *Interruption of agitation of platelet concentrates: effects on in vitro parameters.* Vox Sang 2005; 88:227-234.
2. Van der Meer PF, Bontekoe U, Daal BB, de Korte D. *Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?* Transfusion 2015; 55(8):1900-8.
3. Gulliksson H. *Additive solutions for the storage of platelets for transfusion.* Transfus Med 2000; 10:257-264.
4. Ringwald J, Zimmerman R, Eckstein R. *The New Generation of Platelet Additive Solution for storage at 22°C: Development and current experience.* Transfus Med 2006; 20:158-164.
5. Alhumaidan H, Sweeney J. *Current status of additive solutions for platelets.* J Clin Apher 2012; 27(2):93-8.
6. Gulliksson H. *Platelet storage media.* Vox Sang 2014; 107(3):205-12.
7. Gulliksson H, AuBuchon JP, Vesteninen M, Sandgren P, Larsson S, Pickard CA, Herschel I, Roger J, Tracy JE, Langweiler M. *Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium.* Vox Sang 2002; 82:131-136.
8. de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC. *Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.* Transfusion 2000; 40:398-403.
9. Wagner F, Adamo W. *Reduced rate of adverse reactions to plasma reduced pooled platelet units: possible role of minor incompatible transfusions.* Vox Sang 2006; 91(Suppl.3):P508.
10. Nussbaumer W, Mayersbach P, Mayer W, Gachter E. *Influence of platelet additive solution on frequency of adverse events focused on the ABO-match of the donor with the recipient.* Vox Sang 2012; 103(Suppl.1):P-564.
11. Sandgren P, Stjepanovic A. *High-yield platelet units revealed immediate pH decline and delayed mitochondrial dysfunction during storage in 100% plasma as compared with storage in SSP+.* Vox Sang 2012; 103:55-63.
12. Shchepetov A, Alvarez I. *Haemovigilance report on Macopharma SSP and SSP+ platelet additive solutions.* Macopharma 2016.
13. Greco CA, Zhang JG, Kalab M, Yi QL, Ramirez-Arcos SM, Gyongyossy-Issa MI. *Effect of platelet additive solution on bacterial dynamics and their influence on platelet quality in stored platelet concentrates.* Transfusion 2010; 50:2344-52.
14. Yomtovian R, Jacobs MR. *A prospective bonus of platelet storage additive solutions: a reduction in biofilm formation and improved bacterial detection during platelet storage.* Transfusion 2010; 50(11):2295-300.
15. Tardivel R, Vasse J, Gaucheron S, Lebaudy JP, de la Chapelle TL, Semana G. *A Comparative Study of the Efficiency of Plasma and Additive Solution Preserved Platelet Concentrates.* Vox Sang 2012; 103:247.
16. Daskalakis M, Schulz-Huotari C, Melke B, Klink I, Umhau M. *Performance of the Trima® Accel Version 5.2 in the Collection of Triple Platelet Products plus Plasma.* Transfus Med Hemother 2009; 36(Suppl.1):P3.07.
17. Janetzky S, Thiele T, Hartenstein G, Füll B, Strobel U, Greinacher A. *Production of Platelets Concentrates in Additive Solution Using the COM.TEC Cell Separator.* Transfus Med Hemother 2009; 36(Suppl.1):P3.19.
18. Cid J, Magnano L, Molina P, Diaz-Ricart M, Martinez N, Maymó RM, Puig L, Lozano M, Escolar G, Galán AM. *Automated preparation of whole blood-derived platelets suspended in two different platelet additive solutions and stored for 7 days.* Transfusion 2014; 54(2):426-33.
19. Sandgren P, Hild M, Sjodin A, Gulliksson H. *Storage of buffy-coat-derived platelets in additive solutions: in vitro effects on platelets prepared by the novel TACS system and stored in plastic containers with different gas permeability.* Vox Sang 2010; 99:341-347.
20. Sellsam A, Müller TH. *UV-C irradiation for pathogen reduction of platelet concentrates and plasma.* Transfus Med Hemother 2011; 38:43-54.
21. Mohr H, Gravenmann U, Bayer A, Müller TH. *Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light.* Transfusion 2009; 49:1956-1963.
22. Mohr H, Steil L, Gravenmann U, Thiele T, Hammer E, Greinacher A, Müller TH, Volker U. *A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.* Transfusion 2009; 49:2612-2624.
23. Sandgren P, Tolksdorf F, Struffl WG, Gulliksson H. *In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.* Vox Sang 2011; 101:35-43.
24. Ignatova AA, Karpova OV, Trakhtman PE, Rumantsev SA, Panichev MA. *Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.* Vox Sang 2016; 110(3):244-52.
25. Nasiri S. *Conversion from platelet-rich plasma platelet production to buffy coat platelet component production: benefits and limitations.* JBC 2014; 6(4): 188-207.
26. Murphy S. *Platelets from pooled buffy coats: an update.* Transfusion 2005; 45(4):634-9.
27. Nogawa M, Shiba M, Matsumoto S, Okazaki H, Satake M, Tadokoro K. *Comparison of in vitro characteristics of apheresis-derived platelet concentrates with low residual plasma during storage in different platelet additive solutions.* Vox Sang 2011; 101(Suppl.2):4C-S14-03.
28. Tynngard N, Trinks M, Berlin G. *In vitro properties of platelets stored in three platelet additive solutions.* Transfusion 2012; 52(5):1003-9.
29. Decane M, Rivera P, Sawyer L. *INTERCEPT platelets treated and stored in SSP+ meet Council of Europe standards for in vitro function after 7 days of storage.* Transfus Med Hemother 2009; 36(Suppl.1):1-62.
30. Chavarin P, Cognasse F, Argaud C, Vidal M, de Putter C, Boussoulade F, Ripaud C, Acquart S, Lin L, Garraud O. *In vitro assessment of apheresis and pool buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System).* Vox Sang 2011; 100:247-249.
31. Johnson L, Winter KM, Hartkopf-Theis T, Reid S, Kwok M, Marks DC. *Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.* Transfusion 2012; 52(3):503-9.

*ISBT 128 Terminology for Platelet Additive Solutions.

**Transfusion Related Acute Lung Injury.